Bill Gates backed biotech reveals strategy

June 8, 2018
Medical Communications Bill and Melinda Gates Foundation, biotech, drugs, pharma, pharmaceutical

The Bill and Melina Gates Foundation already funnels a large amount of money into aiding public health, particularly by funding …

cancer_research_uk

Cancer Research UK unveil new Chief Business Officer

June 8, 2018
Medical Communications Cancer Research UK, biotech, drugs, pharma, pharmaceutical

Cancer Research UK has appointed Tony Hickson to the position of Chief Business Officer. He arrives to the business from …

nerves

Parkinson’s disease: A quest for steadier therapies

June 7, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, biotech, drugs, pharma, pharmaceutical

The worrying number of deaths associated with Nuplazid has eyes returning to the pipeline for Parkinson’s disease. Anjali Shukla, a …

J&J looks to trim business with $2.8bn sale

June 7, 2018
Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical

Johnson & Johnson continues to look at options to slim down its business, after having received an offer from Fortive …

Pfizer pumps $600m into venture fund, targeting neuroscience

June 7, 2018
Research and Development, Sales and Marketing Pfizer, biotech, drugs, neuroscience, pharma, pharmaceutical

Pfizer’s move to dump its neuroscience divisions caused serious ripples through the industry, with many wondering whether it heralded an …

money-2180330_960_720

Forty Seven springs out of the blocks ahead of IPO

June 7, 2018
Research and Development, Sales and Marketing Forty Seven, biotech, drugs, pharma, pharmaceutical

Forty Seven, a spinout from Stanford University, has had a busy few days – first announcing that it had filed …

handshake2

Axovant attempts to rise from ashes with $842m Parkinson’s therapy deal

June 7, 2018
Sales and Marketing Axovant, Oxford BioMedica, biotech, drugs, pharma, pharmaceutical

Axovant’s spectacular crash to Earth, after a soaring IPO that saw its share price hit the heady heights of $26, …

FlyPharma Conference Europe concludes its fourth successful year in Brussels

June 7, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, flypharma, pharma, pharmaceutical

The FlyPharma Conference Europe wrapped up for another year on 6 June, returning with an expanded roster of speakers who …

allergan-irvine-california-2_0

Allergan mauled by investors in public letter

June 6, 2018
Medical Communications, Research and Development Allergan

Last week, Allergan announced that a strategic review of its operations had led to a decision to divest its women’s …

mylan_inside_0

Mylan lands biosimilar sucker punch to Amgen’s blockbuster

June 6, 2018
Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta

Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta (pegfilgrastim), setting the companies on track to …

astrazeneca_sign_sky

AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer

June 5, 2018
Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer

In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …

NICE recommends MSD’s Keytruda for advanced PD-L1-positive lung cancer

June 5, 2018
Research and Development MSD, Merck, NHS, NICE, keytruda, pharma

UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS …

Eli Lilly’s President of Oncology to retire

June 5, 2018
Research and Development Cancer, Eli Lilly, appointment, oncology, pharma

Just as it ramps up its cancer-fighting efforts, Eli Lilly has revealed that its Senior Vice President and President of …

bill_hinshaw

Novartis’ US Oncology head makes leap to become biotech CEO

June 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis

The departure of high-level, big pharma executives to tiny biotechs is steadily becoming a constant stream; the latest is Bill …

david_elkins

Celgene bring in new CFO to steady the ship

June 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene

The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing …

shutterstock_273326141

Axovant snatches Teva and Allergan execs to strengthen management

June 5, 2018
Manufacturing and Production, Medical Communications Allergan, Axovant, Teva, appointment, pharma

Axovant has announced reinforcements to its management team with two new additions, snatching up Allergan’s current Chief Medical Officer Dr …

lilly_building_with_american_flag_web

FDA greenlights Lilly’s Olumiant in rheumatoid arthritis, with major caveats

June 5, 2018
Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Olumiant, pharma

Eli Lilly has announced that its oral JAK inhibitor Olumiant (baricitinib) has received FDA approval for the treatment of moderately-to-severely …

2000px-gastric_balloon_icon

FDA links intragastric balloons to 5 more deaths, bringing total to 12 since 2016

June 5, 2018
Manufacturing and Production, Sales and Marketing FDA, gastric balloon, pharma

Five more deaths have been reported to the FDA in patients using intragastric balloon systems, meaning that 12 total deaths …

nektar-therapeutics

“Underwhelming” drug data devastates Nektar, shares fall by 42%

June 5, 2018
Manufacturing and Production, Research and Development ASCO, BMS, Bristol-Myers Squibb, Cancer, Nektar, bristol myers-squibb, pharma

Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …

janssen_latest_logo_on_sign_closer

Janssen debuts promising new cancer data at ASCO

June 4, 2018
Research and Development, Sales and Marketing ASCO, Cancer, J&J, JJ, Jassen, erdafitinib, imbruvica, pharma

Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …

The Gateway to Local Adoption Series

Latest content